AQR Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$591K Buy
31,758
+1,841
+6% +$46.1K ﹤0.01% 3344
2026
Q2
$888K Buy
29,917
+16,731
+127% +$373K ﹤0.01% 3070
2026
Q1
$262K Buy
+13,186
New +$227K ﹤0.01% 3474
2025
Q2
– Sell
-19,034
Closed -$248K – 3413
2025
Q1
$248K Buy
+19,034
New +$253K ﹤0.01% 2776

Other funds holding BCAX

AQR Capital Management's BCAX Position: Q3 2026 in Review

AQR Capital Management increased its Bicara Therapeutics (BCAX) stake by 6.2% in Q3 2026, buying an estimated $46.1K and bringing the position to 31,758 shares worth $591K. The position accounts for ﹤0.01% of the portfolio, ranked #3344.

AQR Capital Management first reported a position in BCAX in Q1 2025 and has held it in 4 quarters since. The position peaked at $888K in Q2 2026. 169 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • AQR Capital Management held 31,758 shares of Bicara Therapeutics worth $591K as of Q3 2026.
  • AQR Capital Management bought 1,841 Bicara Therapeutics shares in Q3 2026, an estimated $46.1K.
  • Bicara Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q3 2026, its #3344 holding.
  • AQR Capital Management first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • AQR Capital Management's Bicara Therapeutics position peaked at $888K in Q2 2026.
  • 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.